SCHEMBL21461684

SCHEMBL21461684

CCCCN(C)c1nc2c(N(Cc3ccccc3)Cc3ccccc3)nc3c(I)cccc3c2n1CC(C)C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.34
TSHR P16473 4/20 0.34
CYP3A4 P08684 1/20 0.34
ALOX15 P16050 1/20 0.34
MAPK1 P28482 1/20 0.34
PIM1 P11309 1/20 0.33
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
LMNA P02545 2/20 0.32
CASP1 P29466 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
HTT P42858 1/20 0.32
CASP7 P55210 1/20 0.32
HSD17B10 Q99714 1/20 0.32
PDE4A P27815 2/20 0.32
PDE4B Q07343 2/20 0.32
PDE4C Q08493 2/20 0.32
PDE4D Q08499 2/20 0.32
TLR7 Q9NYK1 2/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29988385 0.88 TLR7 (0.39) L3MBTL1TSHRCYP3A4ALOX15MAPK1
SCHEMBL146804 0.88 TLR7 (0.39) L3MBTL1TSHRCYP3A4ALOX15MAPK1
SCHEMBL14866402 0.82 TLR7 (0.37) TSHRCYP3A4ALOX15MAPK1PIM1
SCHEMBL12245244 0.76 PIM1 (0.37) TSHRCYP3A4ALOX15PIM1LMNA
SCHEMBL30448090 0.75 TLR7 (0.39) TSHRPIM1LMNACASP1SMN1; SMN2
SCHEMBL143565 0.75 TLR7 (0.39) TSHRPIM1LMNACASP1SMN1; SMN2
SCHEMBL12245205 0.75 TLR7 (0.38) TSHRCYP3A4ALOX15MAPK1PIM1
SCHEMBL3251879 0.74 TLR7 (0.39) L3MBTL1PDE4APDE4BPDE4CPDE4D
SCHEMBL12245236 0.73 TLR7 (0.36) L3MBTL1TSHRPIM1NPC1RAB9A
SCHEMBL31092872 0.73 TLR7 (0.51) LMNAPDE4DTLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190314483-A1 Vaccines Including Antigen From Four Strains of Influenza Virus SEQIRUS UK LTD (GB) 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190314483-A1 Vaccines Including Antigen From Four Strains of Influenza Virus LY96, HLA-B, HAVCR2 L3MBTL1 672/4885TSHR 2999/4885CYP3A4 1812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.